Clarity and consistency in a generic manufacturer's communications regarding a drug marketed under a skinny label may be essential in avoiding liability for induced infringement.
The U.S. Court of Appeals for the Federal Circuit reversed a district court's decision, finding Amarin's allegations against Hikma plausible for induced infringement based on the label and public statements.
[
add
]
[
|
|
...
]